Breaking Finance News

Zacks Investment Research disclosed Express Scripts Holding Company (NASDAQ:ESRX), upping its target price to $78.00 today

Express Scripts Holding Company (NASDAQ:ESRX) had its target price raised to $78.00 by Zacks Investment Research in a report released 10/05/2016. The new target price indicates a potential upside of 0.11% from the company's most recent stock price close.

On Tuesday August 02, 2016, Mizuho Securities released a statement for Express Scripts Holding Company (NASDAQ:ESRX) bumped up the target price from $77.00 to $82.00 that suggested an upside of 0.08%.

Boasting a price of $70.38, Express Scripts Holding Company (NASDAQ:ESRX) traded 0.92% higher on the day. With the last stock price close down -4.34% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Express Scripts Holding Company has recorded a 50-day average of $72.31 and a two hundred day average of $73.75. Volume of trade was down over the average, with 471,117 shares of ESRX changing hands under the typical 3,480,610

Performance Chart

Express Scripts Holding Company (NASDAQ:ESRX)

With a total market value of $0, Express Scripts Holding Company has 52 week low of $65.55 and a 52 week high of $89.20 with a P/E ratio of 17.43 .

In addition to Zacks Investment Research reporting its target price, a total of 18 firms have reported on the stock. The consensus target price is $80.33 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Express Scripts Holding Company (NASDAQ:ESRX)

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States, Canada, and Europe. The company operates through two segments, PBM and Other Business Operations. The companyÂ’s PBM segmentÂ’s products and services include clinical solutions to enhance health outcomes; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, including the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration. It also provides benefit design consultation; drug utilization review; drug formulary management; an array of Medicare, Medicaid, and health insurance marketplace; administration of a group purchasing organization; and consumer health and drug information services. In addition, the company distributes specialty pharmaceuticals and medical supplies to providers, clinics, and hospitals; and offers consulting services, including design, implementation, and project management for pharmaceutical, biotechnology, and device manufacturers to collect scientific evidence to guide the use of medicines. It serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workersÂ’ compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2015, the company operated four automated dispensing home delivery pharmacies; one non-automated dispensing home delivery pharmacy; and one non-dispensing home delivery pharmacy maintained for business continuity purpose, as well as several non-dispensing order processing centers, patient contact centers, specialty drug pharmacies, and fertility pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *